PANCREATIC CANCER

This study tests a new drug called ANO31905 combined with standard chemotherapy as a first treatment for people with a specific type of advanced pancreatic cancer (CLDN18.2-positive). About 84 adults with cancer that cannot be removed by surgery or has spread will take part. The …

This study tests an experimental drug called HRS-7058 in people with advanced pancreatic cancer that has a specific change in the KRAS gene (G12C mutation). Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors …

This study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety, find the best dose, and see if it can s…

This study tests whether adding a focused ultrasound treatment called IMD10 to standard chemotherapy can help people with pancreatic cancer that is either borderline resectable or locally advanced. About 136 adults aged 18 to 85 with confirmed pancreatic ductal adenocarcinoma wil…

This early-phase trial tests a new mix of drugs (nogapendekin alfa inbakicept, sotevtamab, zabadinostat, plus standard chemo) in 30 people with pancreatic cancer that is either borderline resectable or locally advanced. The goal is to see if the combination is safe and can shrink…

This early study tests a new approach for locally advanced pancreatic cancer. Tiny radioactive rods are inserted directly into the tumor to deliver alpha radiation from within, while patients also receive standard chemotherapy. The main goal is to see if the procedure is safe, an…

This study looks at a two-part surgery for people with certain pancreatic tumors who are at high risk for leaks after standard surgery. First, the whole pancreas is removed to eliminate the tumor. Then, the patient's own insulin-producing cells are put back into the liver to help…

This study looks at whether adding Shouhui Tongbian capsules to standard pancreatic enzyme pills can help people who had part of their pancreas removed due to cancer. About 80 adults who have digestive problems or constipation after surgery will take the combination for 12 weeks.…

This early-phase study tests a new drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goal is to check safety and find the best dose. Researchers will also watch for any signs that the drug shrinks tumors.

This early-phase trial tests a new treatment for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given both into the abdomen and through a vein, along …

This study tests a combination of targeted radiation (SBRT) and a chemotherapy regimen called NALIRIFOX in 42 adults with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach can delay cancer growth and improve survival. Partic…

This study tests whether adding the drug adebrelimab to standard chemotherapy before surgery can help shrink pancreatic tumors and improve complete removal. About 30 adults with resectable pancreatic cancer will receive this combination. The goal is to see if it increases the cha…

This early-stage trial tests a new treatment called CAR-M cells, which are immune cells engineered to find and attack a protein called C-MET on pancreatic cancer cells. It is for people with advanced pancreatic cancer whose disease has worsened after chemotherapy. The main goals …

This study tests a new drug (IBI343) combined with chemotherapy given before surgery for people with borderline resectable pancreatic cancer. The goal is to shrink the tumor enough to allow successful removal and improve long-term outcomes. About 40 participants will receive the …

This study tests a new oral drug, BLEX 404, combined with standard chemotherapy (gemcitabine) in 40 adults with advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to find a safe dose and see if the combination shrinks tumors. Participants must…

This study looks at whether adding diabetes medication to standard chemotherapy can help people with metastatic pancreatic cancer who also have diabetes live longer. About 210 adults will receive either chemotherapy alone or chemotherapy plus active diabetes treatment. The main g…

This phase 3 study tests whether adding the experimental drug FG-M108 to standard chemotherapy helps people with a specific type of advanced pancreatic cancer live longer. About 524 adults whose tumors have a protein called Claudin18.2 will receive either FG-M108 or a placebo, pl…

This study tests whether a specific sequence of two chemotherapy combinations, each paired with an immunotherapy drug, can shrink borderline resectable or locally advanced pancreatic cancer enough to allow surgery. About 77 adults with this type of pancreatic cancer will receive …

This early-phase study tests whether adding the experimental drug NP137 to standard chemotherapy (FOLFIRINOX) can change the behavior of pancreatic cancer cells before and after surgery. About 25 adults with resectable pancreatic cancer will receive NP137 plus chemotherapy before…

This study aims to find out which of two surgical reconstruction techniques leads to fewer stomach-emptying problems after pancreatic cancer surgery. Researchers will enroll 124 patients undergoing surgery and randomly assign them to one of the two techniques. They will track rec…

This study will test a new tool called the Odesa Criteria 2026, which uses a point-based system to help doctors diagnose autoimmune pancreatitis. Researchers will check how accurate this tool is by comparing it to the final diagnosis in 82 adults. The goal is to make it easier to…

This study will test a new type of PET scan that looks for a protein called Claudin18.2 in people with pancreatic, stomach, or gastroesophageal junction cancer. The goal is to see how well the scan can find this protein, which may help doctors choose the right targeted therapy. A…

This study tests a new type of PET scan that uses a special probe to find cancers that have a protein called GPA33. The study will include 56 people with suspected or confirmed colorectal, stomach, or pancreatic cancer, as well as healthy volunteers. The goal is to see if this im…

This study is testing a new web-based program designed to help people with pancreatic cancer reduce stress and manage symptoms. Researchers will enroll 60 adults who speak English or Spanish and have pancreatic cancer. The program involves biweekly calls and surveys to see if it'…

This study tests if a smartwatch-guided exercise program helps cancer survivors feel less tired after finishing chemotherapy. About 98 adults with certain cancers (breast, colorectal, ovarian, pancreatic, stomach) will either follow the exercise program or receive standard care. …

This study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve gut symptoms in people who have had surgery to remove a pancreatic tumor. About 158 adults will be randomly assigned to take either the probiotic or a placebo pill for a perio…

This study tests whether a 12-week supervised strength training program can help people with advanced pancreatic cancer preserve muscle mass and improve quality of life. Ten participants will be randomly assigned to either the exercise program or standard care. The goal is to see…

This study tests a quicker way to deliver radiation therapy to ease severe belly pain caused by pancreatic cancer. Normally, planning this treatment takes a week or more because a separate CT scan is needed. Here, doctors will use the patient's existing diagnostic CT scan to plan…

This study looks at whether tumor cells found in the portal vein (a major liver blood vessel) can help predict if pancreatic cancer will come back or spread after surgery. Researchers will collect these cells during an endoscopic ultrasound and combine them with other tests. The …

This study interviews 20 people with pancreatic cancer to learn why some groups—like racial minorities, people with lower incomes, or those in rural areas—are less likely to join clinical trials. Researchers hope to use these insights to make trials more accessible and fair for e…

This study looks at whether a blood test that counts and analyzes circulating tumor cells can predict how well certain cancer drugs (PARP inhibitors) work in people with advanced breast, prostate, pancreatic, or ovarian cancer. Researchers will collect blood samples from 300 adul…

This study collects blood, tissue, and other samples from 300 adults with liver, bile duct, or pancreatic tumors, as well as from people with benign conditions and healthy volunteers. No experimental treatments are given—samples are taken during routine care. The goal is to creat…

This study looks at whether tumor DNA found in blood or belly fluid can predict if stomach, colon, or pancreatic cancer will spread to the lining of the abdomen (peritoneum). Researchers will follow 300 people with early-stage cancers to see if those with positive DNA tests have …

This study will track 2,500 adults in Italy who are getting an endoscopic ultrasound (EUS) because their doctor suspects a pancreatic or bile duct tumor. Researchers want to see how often the biopsy from the scope gives the right diagnosis, how safe the procedure is, and how quic…

This study looks at whether intermittent fasting (a pattern of eating and not eating at set times) is safe and doable for 20 people at high risk for pancreatic cancer. Researchers will track side effects and check for changes in blood markers, inflammation, gut bacteria, and imag…

This study will create a detailed database of 1000 people with KRAS-mutant pancreatic cancer who are receiving targeted therapy. Researchers will track how long participants live and how long their cancer stays under control. The goal is to better understand which treatments work…